Back to search results

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Obesity &Amp; Overweight

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads

  • Philip Ryan, MD

    Principal Investigator

    Nucleus Network Pty Ltd.

View source on ClinicalTrials.gov(opens in a new tab)